Dyslipidemia

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

By

Evolocumab may decrease the risk for adverse cardiovascular events in patients with and without diabetes.

PCSK9 Inhibitor Approved in Less Than Half of Insurance Claims

PCSK9 Inhibitor Approved in Less Than Half of Insurance Claims

Rates of approval for a PCSK9 inhibitor treatment are low overall.

PCSK9 Inhibitor Does Not Affect Cognitive Function

PCSK9 Inhibitor Does Not Affect Cognitive Function

By

Evolocumab is not associated with adverse cognitive effects even when low low-density lipoprotein cholesterol levels have been achieved.

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

By

Serum lipid profile changes were shown to occur within the first year of initiating antiretroviral therapy in children.

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

By

Researchers find statins could be a potential treatment option in COPD.

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less than half of patients prescribed PCSK9 inhibitors receive approval, and only about 30% ever receive therapy.

FDA Approves Pitavastatin for Mixed Dyslipidemia and Hyperlipidemia

FDA Approves Pitavastatin for Mixed Dyslipidemia and Hyperlipidemia

By

The FDA has approved a new pitavastatin for the treatment of primary hyperlipidemia or mixed dyslipidemia.

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Lower incidence of major coronary events for patients with atherosclerotic vascular disease receiving intensive statins is linked with use of anacetrapib.

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Clinical benefit of reduced low-density lipoprotein cholesterol (LDL-C) levels may depend on the corresponding reduction in apolipoprotein B (apoB)-containing lipoprotein particles.

Anti-Tumor Necrosis Factor Drug Improves CV Health in Psoriatic Arthritis

Anti-Tumor Necrosis Factor Drug Improves CV Health in Psoriatic Arthritis

By

Cardiovascular health in psoriatic arthritis improves with anti-tumor necrosis factor drug etanercept.

PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness

PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness

Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease

Antidepressant Mislabeled as Cholesterol Drug: Recall

Antidepressant Mislabeled as Cholesterol Drug: Recall

By

International Laboratories, LLC has issued a recall for one lot of Pravastatin Sodium Tablets 40mg due to mislabeling.

Evolocumab Added to Statin Therapy Does Not Affect Cognition

Evolocumab Added to Statin Therapy Does Not Affect Cognition

There is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy.

Marked Variations in Statin Use in Nursing Home Residents

Marked Variations in Statin Use in Nursing Home Residents

Statin prescribing trends vary among nursing home residents with significant variation of prescribing across physicians.

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

By

Patients with psoriasis have high rates of cardiometabolic comorbidities.

Noncalcified, High-Risk Coronary Plaque Burden Increased With Psoriasis

Noncalcified, High-Risk Coronary Plaque Burden Increased With Psoriasis

By

Individuals with psoriasis have a greater risk for noncalcified coronary plaque burden compared with healthy individuals and patients with hyperlipidemia.

FDA Approves Pitavastatin as Adjunctive Therapy for Hyperlipidemia or Mixed Dyslipidemia

FDA Approves Pitavastatin as Adjunctive Therapy for Hyperlipidemia or Mixed Dyslipidemia

By

The FDA has approved Zypitamag for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia.

Statins Reduce Cardiovascular Events, Death Even With Adverse Reactions

Statins Reduce Cardiovascular Events, Death Even With Adverse Reactions

Statin use after an adverse reaction is associated with lower incidences of cardiovascular events and death.

Glycemic Control Improves With Hepatitis C Treatment

Glycemic Control Improves With Hepatitis C Treatment

Direct-acting antiviral treatment for hepatitis C virus is linked to improved glycemic control in patients with type 2 diabetes.

CVD Risk in Juvenile Idiopathic Arthritis May Be Linked to Vitamin D Levels

CVD Risk in Juvenile Idiopathic Arthritis May Be Linked to Vitamin D Levels

By

Serum Vitamin D levels are related to cholesterol levels and other risk factors for cardiovascular disease in patients with juvenile idiopathic arthritis.

PCSK9 Inhibitor Trends in Type 1 Diabetes

PCSK9 Inhibitor Trends in Type 1 Diabetes

PCSK9 had a significant correlation with hemoglobin A1c, triglycerides, total cholesterol, LDL cholesterol, and apolipoprotein B in patients with type 1 diabetes.

Total Cholesterol, Low-Density Lipoprotein Cholesterol Levels Affect Parkinson's Risk

Total Cholesterol, Low-Density Lipoprotein Cholesterol Levels Affect Parkinson's Risk

By

A decreased risk in Parkinson's disease has been associated with total serum cholesterol and low-density lipoprotein cholesterol in men not on statin therapy.

Statins May Increase Risk for Mortality in Type 2 Diabetes

Statins May Increase Risk for Mortality in Type 2 Diabetes

By

In a study,patients with type 2 diabetes presented better glycemic control and had higher risk for mortality when not taking statins.

Cholesterol Significantly Reduced by Blocking Angiopoietin-like 3 Gene

Cholesterol Significantly Reduced by Blocking Angiopoietin-like 3 Gene

Two research groups successfully reduced cholesterol in humans to block the angiopoietin-like 3 gene.

Refill Synchronization Beneficial for Medication Adherence

Refill Synchronization Beneficial for Medication Adherence

Appointment-based models improve medication-taking behavior.

Dapagliflozin May Benefit Progression of Atherosclerosis

Dapagliflozin May Benefit Progression of Atherosclerosis

By

Dapagliflozin improved endothelial function in patients with type 2 diabetes.

Long-Term Outcomes of Evacetrapib on Cardiovascular Outcomes

Long-Term Outcomes of Evacetrapib on Cardiovascular Outcomes

Evacetrapib does not affect the primary efficacy end point of first occurrence of any component of a composite of death from cardiovascular causes in patients with high-risk vascular disease.

Targeted Approach Needed for Cholesterol Screenings

Targeted Approach Needed for Cholesterol Screenings

Study shows prevalence of atherosclerotic cardiovascular disease risk among adults under 50 without diabetes is low.

Are Patients Aware the Importance of Cholesterol Management?

Are Patients Aware the Importance of Cholesterol Management?

An American Heart Association survey found that patients felt least informed about the differences in cholesterol types and goals for cholesterol management.

Cognition Not Adversely Affected by Evolocumab With Statin Therapy

Cognition Not Adversely Affected by Evolocumab With Statin Therapy

By

No differences were seen in measures of executive function between the evolocumab and placebo groups.

Sign Up for Free e-Newsletters